Testing a new imaging agent for brain and pancreatic tumors
Part of Brain & nervous system, Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-phase study tests a new imaging agent that may help see certain solid tumors (like brain cancer or pancreatic cancer) more clearly. You will receive a single injection of a radioactive tracer, then have several scans over a few days to see where the tracer goes and how long it stays.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with either glioblastoma (a type of brain tumor) or pancreatic cancer, and your tumor is at least 1 cm (pea-sized) on an MRI or CT scan
- You are generally able to take care of most daily tasks (Karnofsky score of 60 or higher)
- Your blood counts and kidney/liver function are within certain limits (your doctor can check)
- You are not pregnant, breastfeeding, and agree to use birth control if needed
- You are not currently taking statin cholesterol medications (or can stop them for a few days before the study)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special imaging scan (PSMA PET) before and after the drug bevacizumab can help see how the drug affects glioblastoma tumors. It aims to understand tumor changes better, which may help guide future treatments.
This trial tests a new type of PET scan that uses a special tracer (FAPI) to get clearer images of pancreatic cancer. The goal is to find cancer earlier and better plan surgery or treatment.
This trial uses special imaging to tell the difference between real brain tumor growth and a treatment reaction that looks like a tumor. It may help you and your doctor decide if a biopsy is needed.
This Phase 1 trial tests a new imaging agent (a radioactive tracer) that helps doctors see pancreatic cancer that has spread or cannot be removed by surgery. The scan uses positron emission tomography (PET), a type of imaging that detects cancer cells.
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
This early-stage trial tests a new experimental drug called HT547 that combines radioactive tracers to help doctors see and treat certain solid tumors (breast, head and neck, pancreatic, or brain cancer). The study will check if the drug is safe, how it moves through your body, and how much radiation it gives you.
Hear when a new Glioblastoma Multiforme (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.